Evidence-based treatment for HIV-associated dementia and cognitive impairement: Why so little?

PLoS Clinical Trials

Volumn 2, Issue 3, 2007, Pages

  Ellis, Ronald J ^a  

^a UNIVERSITY OF SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PLACEBO; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID LEVEL; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DRUG MEGADOSE; DRUG PENETRATION; EVIDENCE BASED MEDICINE; HEALTH CARE ACCESS; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROPSYCHOLOGICAL TEST; PATIENT COMPLIANCE; PRACTICE GUIDELINE; VIRUS INHIBITION; VIRUS LOAD;

EID: 34249811796     PISSN: None     EISSN: 15555887     Source Type: Journal    
DOI: 10.1371/journal.pctr.0020015     Document Type: Article

References (18)

1. Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, et al. (2006) Factors in AIDS dementia complex trial design: Results and lessons from the abacavir trial. PLoS Clin Trials 2: E13. doi:10.1371/journal.pctr.0020013
2. Sidtis JJ, Gatsonis C, Price RW, Singer EJ, Collier AC, et al. (1993) Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 33: 343-349.
3. Portegies P, Enting RH, de Gans J, Algra PR, Derix MM, et al. (1993) Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 7: 669-675.
4. Gray F, Geny C, Dournon E, Fenelon F, Lionnet F, et al. (1991) Neuropathological evidence that zidovudine reduces incidence of HIV infection of brain. Lancet 337: 852-853.
5. Heaton RK, Grant I, Butters N, White DA, Kirson D, et al. (1995) The HNRC 500-Neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1: 231-251.
6. Stern Y, Liu X, Marder K, Todak G, Sano M, et al. (1995) Neuropsychological changes in a prospectively followed cohort of homosexual and bisexual men with and without HIV infection. Neurology 45: 467-472.
7. Ellis RJ, Deutsch R, Heaton RK, Marcotte TD, McCutchan JA, et al. (1997) Neurocognitive impairment is an independent risk factor for death in HIV infection. San Diego HIV Neurobehavioral Research Center Group. Arch Neurol 54: 416-424.
8. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, et al. (1999) Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 13: 1249-1253.
9. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, et al. (2000) Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 69: 376-380.
10. Ferrando SJ, Rabkin JG, van Gorp W, Lin SH, McElhiney M (2003) Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J Neuropsychiatry Clin Neurosci 15: 208-214.
11. Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ (2003) Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS 17: 1539-1545.
12. Tozzi V, Balestra P, Lorenzini P, Bellagamba R, Galgani S, et al. (2005) Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: Results from an urban observational cohort. J Neurovirol 11: 265-273.
13. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, et al. (2002) HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8: 136-142.
14. Letendre SL, McCutchan JA, Childers ME, Woods SP, Lazzaretto D, et al. (2004) Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 56: 416-423.
15. United States Department of Health and Human Services (2006) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available: http://aidsinfo.nih.gov/Guidelines/ GuidelineDetail.aspx?MenuItem=Guidelines&Search= Off&GuidelineID=7&ClassID=1. Accessed 20 February 2007.
16. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, et al. (2006) Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. Top HIV Med 14: 827-843.
17. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, et al. (2007) Memantine and HIV-associated cognitive impairment: A neuropsychological and proton magnetic resonance spectroscopy study. AIDS. In press.
18. Woods SP, Childers M, Ellis RJ, Guaman S, Grant I, et al. (2006) A battery approach for measuring neuropsychological change. Arch Clin Neuropsychol 21: 83-89.